Fenwick represented Sempre Health, a leading solution for behavior-based healthcare pricing, in its $15 million Series B financing. The round was led by the Blue Venture Fund. UPMC Enterprises and existing investors Rethink Impact, LifeForce Capital and Industry Ventures also participated.
The funding will be used to advance Sempre's two-sided network of payors and pharma manufacturers nationwide and further grow the number of chronic disease patients Sempre can help better afford and access their medications. More information about the financing can be found in the company’s announcement.
The Fenwick team included corporate partners Michael Esquivel and Patrick Grilli and associate Corinne Nhaissi.